炎症免疫在冠心病领域的研究进展

悦 高(内蒙古医科大学，中国;)
云 吴(内蒙古自治区人民医院，中国;)

摘要

冠状动脉粥样硬化是一种由多种炎症细胞及炎症因子共同参与的慢性炎症性疾病。目前，多种新型炎症生物标志物已被证实与冠状动脉粥样硬化性心脏病发生、冠状动脉狭窄严重程度以及疾病的不良预后密切相关。由此，而引发的使用抗炎治疗进一步降低冠心病的风险残余成为未来冠心病治疗的新希望。论文就近年开展的炎症生物标志物与冠心病进展的相关性及冠心病抗炎治疗策略的进展做一综述，探索炎症生物标志物与冠心病发生及进展的相关性或可为冠心病的诊断及治疗提供新的思路。

关键词

冠状动脉粥样硬化性心脏病；炎症生物标志物；抗炎治疗

参考

《中国心血管健康与疾病报告2021》要点解读[J].中国心血管杂志,2022,27(4):305-318.

Massimo F, G A B, Francesco B, et al. Stress and Inflammation in Coronary Artery Disease: A Review Psychoneuroendocrineimmunology-Based.[J].Frontiers in immunology,2018,92031.

Collaboration ( T T C .Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials[J].The Lancet,2010,376(9753):1670-1681.

Alexander RW. Inflammation and coronary artery disease[J].The New England journal of medicine,1994,331(7):468-469.

Tamhane U U ,Aneja S ,Montgomery D , et al.Association Between Admission Neutrophil to Lymphocyte Ratio and Outcomes in Patients With Acute Coronary Syndrome[J].The American Journal of Cardiology,2008,102(6):653-657.

Kalay N ,Dogdu O ,Koc F , et al.Hematologic Parameters and Angiographic Progression of Coronary Atherosclerosis[J].Angiology,2012,63(3):213-217.

Kaya A, Kurt M, Tanboga İ, et al. PP-234 RELATION OF NEUTROPHIL TO LYMPHOCYTE RATIO WITH PRESENCE AND SEVERITY OF STABLE CORONARY ARTERY DISEASE[J]. International Journal of Cardiology,2013,163(3S1):S173-S173.

Eman M K ,Simón F M .Megakaryocyte Diversity in Ontogeny, Functions and Cell-Cell Interactions [J].Frontiers in Oncology,2022,12840044-840044.

Niema K, Felix H, Lorenz K, et al. The age-specific prognostic impact of the platelet-to-lymphocyte ratio on long-term outcome after acute coronary syndrome[J]. European heart journal open,2022,2(1):oeab031.

GAFAR A A, DEN E E N M, M.Sc., et al. The Relation between Platelet to Lymphocyte Ratio with Severity And Complexity of Coronary Heart Disease in Patients with Acute ST- Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[J]. The Medical Journal of Cairo University,2019,87(June):2033-2044.

Yehong L, Ting Y, Liang C , et al. Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease[J]. Coronary Artery Disease,2021.

王洁,龙霖梓,曲华,等.系统免疫炎症指数与冠心病预后关系的Meta分析[J].中国循证医学杂志,2023,23(10):1143-1147.

杲建波,马瑞聪,刘春蕊,等.全身免疫炎症指数对急性心肌梗死患者直接经皮冠状动脉介入治疗术后院内主要不良心血管事件的预测价值[J].临床急诊杂志,2022,23(3):192-197.

Qiuxuan L, Xiaoteng M, Qiaoyu S, et al. Prognostic Impact of Multiple Lymphocyte-Based Inflammatory Indices in Acute Coronary Syndrome Patients [J].Frontiers in Cardiovascular Medicine,2022,9811790-811790.

M P R, M B E, Tom T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease[J].The New England journal of medicine,2017,377(12):1119-1131.

M P R, M B E, Aruna P, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events[J].The New England journal of medicine,2019,380(8):752-762.

Leung Y Y, Hui Y L L, Kraus B V. Colchicine—Update on mechanisms of action and therapeutic uses[J].Seminars in Arthritis and Rheumatism,2015,45(3):341-350.

J G M ,Stacy R, Jennifer B, et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome[J].Journal of the American Heart Association,2015,4(8):e002128.

B D C, Aaron R L, Laura S, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout[J]. The Journal of rheumatology, 2012,39(7):1458-64.

Nidorf M S, Eikelboom W J, Budgeon A C, et al. Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease[J]. Journal of the American College of Cardiology,2013,61(4):404-410.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i12.22885